Crisaborole ointment compared with tacrolimus ointment for psoriasis in skin folds and genital areas
Compares two skin ointments for psoriasis in skin folds or genital areas in adults.
Plain-language title generated from the registry record
Registry title: Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis.
Key facts
- Where
- Cairo, EgyptSee the site
- Phase
- Phase 3
Where in Egypt
- Faculty of Medicine Cairo UniversityCairo, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cairo University
- Trial code
- NCT07892339
- Record updated
- 27 October 2026
- Original description
The goal of this clinical trial is to learn if topical application of crisaborole 2% ointment can treat flexural and/or genital psoriasis in adult patients of both genders. It will also learn about the safety of crisaborole 2% ointment.Read full original descriptionShow less
Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis: A Prospective Randomized Controlled Study.
The goal of this clinical trial is to learn if topical application of crisaborole 2% ointment can treat flexural and/or genital psoriasis in adult patients of both genders. It will also learn about the safety of crisaborole 2% ointment.
The main questions it aims to answer is:
* Does crisaborole 2% ointment work effectively in flexural and/or genital psoriasis in adults? * is crisaborole 2% ointment well tolerated in flexural and/or genital psoriasis in adults? * Is crisaborole 2% ointment comparable to tacrolimus 0.1% ointment in terms of efficacy and safety in flexural and/or genital psoriasis in adults?
Researchers will compare crisaborole 2% ointment to tacrolimus 0.1% ointment to see if crisaborole works as effective and is as well-tolerated.
Participants will:
* apply topical crisaborole 2% ointment or tacrolimus 0.1% ointment twice daily for 6 weeks to plaques of flexural and/or genital psoriasis. * Visit the clinic once every 2 weeks for checkups and photography. * Keep a diary of their symptoms.
Inclusion: Adults (≥18 years) of both genders; A confirmed clinical and dermoscopic diagnosis of intertriginous and/or anogenital psoriasis; PASI<10% and /or BSA<10%; Target Lesion Severity Score (TLSS) ≥ 3.
Exclusion: Clinical or mycological evidence of concurrent fungal or bacterial infection in the target area; Immunosuppressive conditions or concurrent immunosuppressive therapy; Use of phototherapy within 1 month prior to enrollment; Use of any topical antipsoriatic therapies within 1 month prior to enrollment; Use of any systemic antipsoriatic therapies within 3 months for conventional systemic agents or biologics, extending to 6 months for patients previously on acitretin; A documented history of hypersensitivity or severe cutaneous reactions to any component of the active study medications (crisaborole or tacrolimus); Generalized Plaque Psoriasis ≥ 10% BSA and /or PASI ≥ 10; Erythrodermic and Pustular Psoriasis; Associated PSA or Other Co-morbidities; Pregnant and lactating females; Pre-existing signs of skin atrophy, telangiectasia or striae in the target area.